Akebia Therapeutics (AKBA) Misses Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Akebia Therapeutics (AKBA) PT Lowered to $18 at Needham & Company
August 9, 2018 1:40 PM EDTNeedham & Company lowered its price target on Akebia Therapeutics (NASDAQ: AKBA) to $18.00 (from $20.00) while maintaining a Buy rating.
Analsyt Chad Messer notes vadadustat pivotal readouts were pushed out. "We continue to expect that INNO2VATE will be fully enrolled by YE:18; however,... More
